TUMOUR MARKERS have been investigated for over 20 years as a possible means of early diagnosis or assessment of response to treatment. In a number of caseschoriocarcinoma, teratoma, adenocarcinoma of the colon certain markers have been of value in assessing therapeutic responses and for the detection of tumour recurrence. No marker is yet specific enough to assist in early diagnosis. Teratoma of the testis can produce two markers-human chorionic gonadotrophin (HCG) and Alpha-foetoprotein (AFP); seminoma, on the other hand, is not known to produce a chemically useful marker.
It has been known for many years that serum lactate dehydrogenase (LDH) is elevated in patients with bulky metastatic disease (Brindley & Francis, 1963: Hill & Levi, 1954) . This nonspecific marker has not been widely used as it is produced by numerous tumours (Goldman et al., 1964) . Recently however it has been suggested that isoenzyme I of LDH may be of value as a marker for testicular tumours (Wampler & Hayra, 1977) . In this paper evidence is presented that serum LDH may be of value in identifying patients with advanced seminoma once the diagnosis of seminoma is confirmed, and in assessing the response of patients to treatment.
Thirty-six patients with seminoma of the testis were referred to the Christie HBospital and Holt Radium Institute over an 8-month period. Thirty-two patients had had an orchidectomy performed at another hospital, 2 patients had had a laparotomy and one patient a biopsy of an inguinal node. In one patient the orchidectomy was carried out at the Christie Hospital. This latter patient and one other with advanced disease were seen before surgery. All others were referred after surgery. The pathological material was reexamined in every case. These patients were assesse(I for the presence of certain tumour markers in their serum. Two further patients who had relapsed after an earlier treatment and who were treated during this period are also included in the study. All patients had chest radiology and i.v. urography. Computer-assisted tomography was performed only in patients in whom there was clinical or radiological suspicion of para-aortic disease.
The staging system used at the Christie Hospital is shown in Table I AFP and HCG were measured by radioimmunoassay. The HCG assays were performed at Charing Cross Hospital and AFP was assayed at the Regional Laboratories in Manchester. The enzymes LDH, y-glutamyl transferase (GGT), alkaline phosphatase (Alk P), aspartate transferase (AST) and alanine transferase (ALT) were assayed in the routine biochemistry laboratory at Withington Hospital, Manchester. Ten ml of clotted blood were collected from the patient on admission for radiotherapy before his first treatment. Control levels were those previously established by the Biochemistry Laboratory at Withington. No attempt was made to study the levels of the different isoenzymes of LDH.
The study was partly retrospective. Some assays were not carried out on all of the patients (Table II) . Seven markers were evaluated for the detection of bulk disease and, in the case of LDH, for the assessment of response to treatment (Table II) .
AFP was elevated in 1/30 cases. This patient had liver metastases. HCG was elevated in 5/31 cases all of whom had advanced disease. Three patients with advanced disease, however, had normal levels. An elevated level did not signify a poor prognosis.
Four enzymes, GGT, Alk P, AST and ALT were also assessed as potential markers. Table (II) . Nine of 37 patients had elevated Alk P levels. Two of the 9 cases had early disease. Two patients with advanced disease had normal values. Two of 37 patients had elevated AST levels, one of these had early disease. Nine patients with advanced disease had normal levels. Six of 37 patients had elevated levels of ALT levels. Four of six patients had "early" disease. Two of 38 patients had elevated y-GGT levels. Both patients had advanced disease. Nine of 1 patients with advanced disease had normal levels.
Of the 7 markers assessed LDH appeared to be the only one of value. None of the 27 patients with "early" disease had elevated values. Nine of the 11 patients with advanced disease had values out with the normal range ( Fig. 1) and one was borderline. The patient with a normal LDH level and advanced disease presented with a recurrence.
In 10/11 advanced cases LDH was monitored during treatment and subsequent follow up (Figs 2, 3 & 4) . In 7 cases the level returned to normal following initial treatment and subsequent investigation revealed complete resolution of disease. In 3 cases radiotherapy failed to control the disease and bring the LDH level into the normal range; all had clinical evidence of residual disease. One of these patients died, 2 responded to further treatment (chemotherapy) although one has residual disease. In one patient on follow-up a raised LDH level was noted 2 months before mediastinal adenopathy became radiologically apparent.
This study was initiated when one of our patients with Stage IV disease was found to have grossly elevated LDH levels, while other liver and cardiac enzymes were normal. It utilized established assays for enzymes and tumour markers which are readily available to the clinician at routine regional and supra regional laboratories.
Of the 7 markers evaluated in the present study on 38 patients, only LDH showed an association between raised levels and advanced disease. No attempt was made to identify any of the individual isoenzymes of which the LDH is composed.
AFP was elevated in only one case out of 30 and this patient had extensive liver involvement. It is suggested that AFP should be routinely determined in all patients with testicular tumours at first presentation. However, if the intial value is normal and the pathological diagnosis is seminoma then subsequent estimations are unhelpful.
Approximately 16% of those in whom HCG was estimated had elevated levels. All the patients with elevated levels had 100000- The four enzymes, GGT, Alk P, AST and ALT proved to be of no value as potential markers (Table II) . Elevated levels of these enzymes were not necessarily an indication of advanced disease.
LDH has been known for many years to be elevated in patients with metastatic disease (Hill & Levi, 1954) . It is also elevated in patients with viral hepatitis, cirrhosis, biliary tract disease and myocardial infarction. As a nonspecific indicator of bulk disease, LDH has been studied in patients with colorectal cancer (Beck et al., 1979) , gastric cancer (CardaAbella et al., 1978) , uterine cancer (Marshall et al., 1979) and testicular tumours. [1981] [1982] FIG. 3-LDH levels of patients with advanced disease during and after treatment. In the majority of advanced cases LDH was estimated regularly during treatment and thereafter on follow-up. In 4 of the 5 cases with Stage IIB disease the LDH level returned to normal during treatment; the results of 3 of these are shown in Fig. 2 . The levels have remained normal after completion of treatment. In one case in which the patient had IIB disease (Fig. 3) , the level fell initially with abdominal X-ray treatment but did not return to normal. It was assumed that the patient had residual disease and a supraclavicular node was found at first followup. Combination chemotherapy was initiated and subsequent assessment has shown complete remission with return to normal of the LDH level.
Two patients with advanced disease (Fig. 3) did not respond to treatment. In one case XRT was stopped and chemo- LDH as measured in routine biochemistry laboratories is made up of 5 isoenzymes-the percentage of each isoenzyme may vary from patient to patient depending upon the source of the majority of the enzyme. Blanco & Linkman (1963) reported a unique form of LDH in postpubertal testes and sperm. Goldberg (1963) reported that the LDH-X of Blanco & Linkman was similar to LDH IV. Despite the reports of high levels of LDH IV/LDH-X in normal adult testes, Wampler & Hayra (1977) reported that LDH-1 was elevated in 2 patients with testicular tumours. Marshall et al. (1979) and Carda-Abella et al. (1978) have recorded changes in isoenzyme patterns in tumours arising at other sites. The 2 groups have suggested that the shift may be due to changes in metabolism in the tumour cells, possibly due to reduction in available oxygen in bulky tumours. Variations in amounts of specific isoenzymes may therefore only be an indication of bulky tumours and not an indication of the total tumour mass.
